Skip to Content

Opthea Ltd CKDXF

Morningstar Rating
$0.29 −0.13 (30.95%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CKDXF is trading at a 484% premium.
Price
$0.29
Fair Value
$7.37
Uncertainty
Extreme
1-Star Price
$27.98
5-Star Price
$4.99
Economic Moat
Bpvw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CKDXF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.42
Day Range
$0.290.29
52-Week Range
$0.290.82
Bid/Ask
$0.29 /
Market Cap
$135.41 Mil
Volume/Avg
130 / 130

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1,361.50
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
24

Comparables

Valuation

Metric
CKDXF
OPCH
MDXG
Price/Earnings (Normalized)
26.5134.42
Price/Book Value
3.436.51
Price/Sales
1,361.501.143.18
Price/Cash Flow
12.6814.98
Price/Earnings
CKDXF
OPCH
MDXG

Financial Strength

Metric
CKDXF
OPCH
MDXG
Quick Ratio
5.001.252.50
Current Ratio
5.101.773.29
Interest Coverage
−7.528.148.24
Quick Ratio
CKDXF
OPCH
MDXG

Profitability

Metric
CKDXF
OPCH
MDXG
Return on Assets (Normalized)
−112.50%9.23%50.04%
Return on Equity (Normalized)
−12,742.05%20.96%184.85%
Return on Invested Capital (Normalized)
−10,051.29%13.01%108.26%
Return on Assets
CKDXF
OPCH
MDXG
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
JzlkzcgqwyBjr$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
MswwnylxVfwjfz$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
JbnfcbhyGzkllh$116.0 Bil
Moderna Inc
MRNA
ZvhghpqqPvmlk$51.1 Bil
argenx SE ADR
ARGX
QgvklcqjBvcv$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
RlfqcxgYttfykx$21.0 Bil
BioNTech SE ADR
BNTX
KsrkbrdqXjtb$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
StcygmcxWdxpch$15.9 Bil
United Therapeutics Corp
UTHR
VfpxqhwbXnssd$14.0 Bil
Incyte Corp
INCY
ZrvjbfwSbxkggg$12.5 Bil

Sponsor Center